The Cellular, Tissue and Gene Therapies Advisory Committee — formerly called the Biological Response Modifiers Advisory Committee — reviews and evaluates available data relating to the safety, effectiveness, and appropriate use of human cells, human tissues, gene transfer therapies, and xenotransplantation products that are intended for transplantation, implantation, infusion, and transfer in the prevention and treatment of a broad spectrum of human diseases and in the reconstruction, repair or replacement of tissues for various conditions. Members of the committee include authorities knowledgeable in the fields of cellular therapies, tissue transplantation, hematology/oncology, and human tissues and transplantation, among other specialties.
REGULATORY UPDATE: FDA Releases 2023 Guidance Agenda
January 31, 2023
On-Demand CABP Exam Opens Feb. 15
January 31, 2023
AABB/ISCT Joint Working Group Releases GTP Interpretative Tool
January 25, 2023